United Therapeutics (UTHR) Set to Announce Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is set to issue its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $5.63 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.67 earnings per share. On average, analysts expect United Therapeutics to post $23 EPS for the current fiscal year and $25 EPS for the next fiscal year.

United Therapeutics Trading Down 1.1 %

UTHR stock traded down $2.71 during mid-day trading on Tuesday, reaching $235.55. The company’s stock had a trading volume of 86,745 shares, compared to its average volume of 434,648. The company has a market cap of $11.08 billion, a price-to-earnings ratio of 12.01 and a beta of 0.52. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $261.54. The business’s 50 day moving average price is $234.21 and its 200 day moving average price is $228.80. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,756.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,756.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total value of $1,290,060.00. Following the completion of the sale, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The disclosure for this sale can be found here. In the last three months, insiders have sold 140,590 shares of company stock worth $33,086,361. 12.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on UTHR shares. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wedbush reiterated an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. HC Wainwright reiterated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. SVB Leerink began coverage on United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective on the stock. Finally, The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and upped their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.